In the ELIXA and the EXSCEL trials, GLP-1RAs (once daily lixisenatide and once weekly exenatide, respectively) didnt provide benefit in MACE reduction compared to placebo, but were non-inferior to placebo for the primary composite outcome of MACE
References: Cani PD et al., 2019 Written by Ali Rza Akn Microbiome Scientist, Author & Founder of Next-Microbiome Ali Rza Akn is a microbiome scientist with nearly 30 years of experience in translational biotechnology, systems biology, and applied microbiome research, spanning discovery, preclinical development, and clinical-stage translation
Some patients using weight loss injections report eating considerably less than before treatment, which may contribute to feeling cold
Shared decision-making throughout the care of the postoperative bariatric surgery patient, especially in these clinical situations, is important
There are two different messages here, Dondarski said